Skip to search formSkip to main contentSkip to account menu

ipilimumab

Known as: MOAB-CTLA-4, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, monoclonal antibody CTLA-4 
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4… 
National Institutes of Health

Related topics

Related topics

16 relations
10 ML ipilimumab 5 MG/ML Injection10 ML ipilimumab 5 MG/ML Injection [Yervoy]CP-675,206CTLA4 protein, human

Narrower (3)

BMS-734016MDX-010Yervoy

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
486 Background: In HCC, surgical resection is associated with high recurrence rates, and no effective neoadjuvant or adjuvant… 
Highly Cited
2018
Highly Cited
2018
Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors
Review
2016
Review
2016
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Highly Cited
2015
Highly Cited
2015
Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
Meeting abstracts Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that is expressed in many cancers and… 
Highly Cited
2014
Highly Cited
2014
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Of 93 patients with pretreated, BRAFV600 mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n… 
Review
2012
Review
2012
Treatment of Melanoma Brain Metastases: A New Paradigm
AbstractBrain metastases occur commonly in patients with metastatic melanoma, are associated with a poor prognosis, and cause… 
Highly Cited
2009
Highly Cited
2009
Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis
Background and aims: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to act as a negative regulator of T cell… 
Highly Cited
2005
Highly Cited
2005
Regulation of murine chronic colitis by CD4+CD25– programmed death‐1+ T cells
Naturally arising CD4+CD25+ regulatory T (TR) cells are engaged in the maintenance of self tolerance and prevention of autoimmune… 
Highly Cited
2003
Highly Cited
2003
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
Previously using a series of monovalent vaccines, we demonstrated that the optimal method for inducing an antibody response… 
2000
2000
Blockade of CTLA-4 Signals Inhibits Th2-Mediated Murine Chronic Graft-Versus-Host Disease by an Enhanced Expansion of Regulatory CD8+ T Cells1
CTLA-4 (CD152) is thought to be a negative regulator of T cell activation. Little is known about the function of CTLA-4 in Th2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)